Related references
Note: Only part of the references are listed.The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy
M. O. Holmstrom et al.
LEUKEMIA (2018)
Sorted peripheral blood cells identify CALR mutations in B- and T-lymphocytes
Lasse Kjaer et al.
LEUKEMIA & LYMPHOMA (2018)
Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms
Alessandro Prestipino et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients
Bei Jia et al.
BLOOD CANCER JOURNAL (2018)
Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response
Morten Orebo Holmstroem et al.
ONCOIMMUNOLOGY (2018)
Spontaneous T-cell responses against Arginase-1 in the chronic myeloproliferative neoplasms relative to disease stage and type of driver mutation
Mia Aaboe Jorgensen et al.
ONCOIMMUNOLOGY (2018)
NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome
Elizabeth A. Griffiths et al.
CLINICAL CANCER RESEARCH (2018)
Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia
Peter G. Maslak et al.
BLOOD ADVANCES (2018)
Does ruxolitinib prolong the survival of patients with myelofibrosis?
Francisco Cervantes et al.
BLOOD (2017)
The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms
M. O. Holmstrom et al.
LEUKEMIA (2017)
PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies
M. H. Qazilbash et al.
LEUKEMIA (2017)
The impact of interferon-alpha2 on HLA genes in patients with polycythemia vera and related neoplasms
Vibe Skov et al.
LEUKEMIA & LYMPHOMA (2017)
Acute myeloid leukemia with mutated nucleophosmin 1: an immunogenic acute myeloid leukemia subtype and potential candidate for immune checkpoint inhibition
Jochen Greiner et al.
HAEMATOLOGICA (2017)
Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia
E. Bernson et al.
LEUKEMIA (2017)
Myeloproliferative Neoplasms
Jerry L. Spivak
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The clinicopathological and prognostic role of thrombocytosis in patients with cancer: A meta-analysis
Xiaojing Zhang et al.
ONCOLOGY LETTERS (2017)
Acute myeloid leukemia with mutated nucleophosmin 1: an immunogenic acute myeloid leukemia subtype and potential candidate for immune checkpoint inhibition
Jochen Greiner et al.
HAEMATOLOGICA (2017)
Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia
Anne M. Dickinson et al.
FRONTIERS IN IMMUNOLOGY (2017)
Calreticulin promotes immunity and type I interferon-dependent survival in mice with acute myeloid leukemia
Xiufen Chen et al.
ONCOIMMUNOLOGY (2017)
Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia
Sebastien Anguille et al.
BLOOD (2017)
Platelets subvert T cell immunity against cancer via GARP-TGFβ axis
Saleh Rachidi et al.
SCIENCE IMMUNOLOGY (2017)
Interferon-α induces marked alterations in circulating regulatory T cells, NK cell subsets, and dendritic cells in patients with JAK2V617F-positive essential thrombocythemia and polycythemia vera
Caroline H. Riley et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2016)
Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism
C. Krupka et al.
LEUKEMIA (2016)
Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia
Anna Martner et al.
ONCOIMMUNOLOGY (2016)
Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms
Marito Araki et al.
BLOOD (2016)
Generating Peripheral Blood Derived Lymphocytes Reacting Against Autologous Primary AML Blasts
Rohtesh S. Mehta et al.
JOURNAL OF IMMUNOTHERAPY (2016)
The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms
M. O. Holmstrom et al.
LEUKEMIA (2016)
Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm
Jen Chin Wang et al.
LEUKEMIA RESEARCH (2016)
Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions
Jacalyn Rosenblatt et al.
Science Translational Medicine (2016)
Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy
Pragya Srivastava et al.
ONCOTARGET (2016)
PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine
Shamaila Munir Ahmad et al.
ONCOIMMUNOLOGY (2016)
Changes in peripheral blood lymphocytes in polycythemia vera and essential thrombocythemia patients treated with pegylated-interferon alpha and correlation with JAK2V617F allelic burden
Magdalena Kovacsovics-Bankowski et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2016)
WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides
Jason Brayer et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment
Frauke M. Schnorfeil et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Altered HLA Class I Profile Associated with Type A/D Nucleophosmin Mutation Points to Possible Anti-Nucleophosmin Immune Response in Acute Myeloid Leukemia
Katerina Kuzelova et al.
PLOS ONE (2015)
Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation
Andreas D. Orskov et al.
ONCOTARGET (2015)
Survival of patients with chronic myeloproliferative neoplasms and new primary cancers: a population-based cohort study
Henrik Frederiksen et al.
LANCET HAEMATOLOGY (2015)
Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α
Caroline H. Riley et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2015)
Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia
Carol O'Hear et al.
HAEMATOLOGICA (2015)
CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330
Christina Krupka et al.
BLOOD (2014)
Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses
Benjamin Uttenthal et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Circulating YKL-40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory state
Mads Emil Bjorn et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2014)
Cytokine profiles in polycythemia vera and essential thrombocythemia patients: Clinical implications
Emmanuel Pourcelot et al.
EXPERIMENTAL HEMATOLOGY (2014)
Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway
S. M. Ahmad et al.
LEUKEMIA (2014)
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
H. Yang et al.
LEUKEMIA (2014)
The platelet-cancer loop in myeloproliferative cancer. Is thrombocythemia an enhancer of cancer invasiveness and metastasis in essential thrombocythemia, polycythemia vera and myelofibrosis?
Hans Carl Hasselbalch
LEUKEMIA RESEARCH (2014)
Immunogenic Cell Death in Cancer Therapy
Guido Kroemer et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment
Francis Mussai et al.
BLOOD (2013)
T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia
Armen Mardiros et al.
BLOOD (2013)
Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut)
Jochen Greiner et al.
BLOOD (2013)
HLA-Restricted CTL That Are Specific for the Immune Checkpoint Ligand PD-L1 Occur with High Frequency in Cancer Patients
Shamaila Munir et al.
CANCER RESEARCH (2013)
Induction of myelodysplasia by myeloid-derived suppressor cells
Xianghong Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Donor Lymphocyte Infusion Induces Polyspecific CD8+ T-Cell Responses With Concurrent Molecular Remission in Acute Myeloid Leukemia With NPM1 Mutation
Susanne Hofmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Functional characterization of Foxp3-specific spontaneous immune responses
S. K. Larsen et al.
LEUKEMIA (2013)
A role for reactive oxygen species in JAK2V617F myeloproliferative neoplasm progression
C. Marty et al.
LEUKEMIA (2013)
Whole blood transcriptional profiling reveals significant down-regulation of human leukocyte antigen class I and II genes in essential thrombocythemia, polycythemia vera and myelofibrosis
Vibe Skov et al.
LEUKEMIA & LYMPHOMA (2013)
Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia
David S. Ritchie et al.
MOLECULAR THERAPY (2013)
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
J. Nangalia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Thorsten Klampfl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Heads or tails? Choosing a salvage therapy for relapsed/refractory Hodgkin lymphoma
Alan P. Skarbnik et al.
EXPERT REVIEW OF HEMATOLOGY (2013)
T cells of patients with myelodysplastic syndrome are frequently derived from the malignant clone
Suzanne M. Vercauteren et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Long-term WT1 peptide vaccination for patients with acute myeloid leukemia with minimal residual disease
A. Tsuboi et al.
LEUKEMIA (2012)
Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: Identification of deregulated genes of significance for inflammation and immune surveillance
Vibe Skov et al.
LEUKEMIA RESEARCH (2012)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Natural CD4+ T-Cell Responses against Indoleamine 2,3-Dioxygenase
Shamaila Munir et al.
PLOS ONE (2012)
Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study
Henrik Frederiksen et al.
BLOOD (2011)
Increase in circulating CD4+CD25+Foxp3+ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-α
Caroline Hasselbalch Riley et al.
BLOOD (2011)
Elevated frequencies of CD4+CD25+CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia
Zhang Shenghui et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
Ayalew Tefferi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Interferon-α in acute myeloid leukemia: an old drug revisited
S. Anguille et al.
LEUKEMIA (2011)
The DNA demethylating agent 5-aza-2′-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells
Maika Almstedt et al.
LEUKEMIA RESEARCH (2010)
Complete molecular response in CML after p210 BCR-ABL1-derived peptide vaccination
Monica Bocchia et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS
Ulrich Keilholz et al.
BLOOD (2009)
Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts
Rifca Le Dieu et al.
BLOOD (2009)
BCR/ABL-specific CD8(+) T cells can be detected from CML patients, but are only expanded from healthy donors
Sylvie Rusakiewicz et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Increased Frequency and Suppression by Regulatory T Cells in Patients with Acute Myelogenous Leukemia
Miroslaw J. Szczepanski et al.
CLINICAL CANCER RESEARCH (2009)
High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome
M. E.D. Chamuleau et al.
HAEMATOLOGICA (2008)
Immunotherapy of established (pre) malignant disease by synthetic long peptide vaccines
Cornelis J. M. Melief et al.
NATURE REVIEWS CANCER (2008)
Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies
Katayoun Rezvani et al.
BLOOD (2008)
CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS)
Shahram Y. Kordasti et al.
BLOOD (2007)
BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells
Katharina M. Brauer et al.
CANCER RESEARCH (2007)
The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders
Thomas Stauffer Larsen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera
Zeyu Xiong et al.
CLINICAL IMMUNOLOGY (2007)
Calreticulin exposure dictates the immunogenicity of cancer cell death
Michel Obeid et al.
NATURE MEDICINE (2007)
Flt3-ITD mutations can generate leukaemia specific neoepitopes:: Potential role for immunotherapeutic approaches
S Scholl et al.
LEUKEMIA & LYMPHOMA (2006)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.
B Falini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species
S Kusmartsev et al.
JOURNAL OF IMMUNOLOGY (2004)
Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules
Z Berke et al.
LEUKEMIA (2000)
Share Paper
